Teleflex Resorbable Magnesium Scaffold demonstrates sustained long-term safety in four-year study

Teleflex (NYSE:TFX) announced positive four-year follow-up data from its First-in-Human BIOMAG-I clinical trial, reinforcing the long-term safety and performance stability of its third-generation Freesolve Resorbable Magnesium Scaffold.

The clinical findings, which were presented at the EuroPCR interventional cardiology conference in Paris, France, track the progress of 116 patients enrolled exclusively across European medical centers.

The updated data showed no new cardiac-related events observed between the two-year and four-year follow-up intervals, signaling a durable plateauing of complications well after the physical implant has fully resorbed into the body.

According to the data presented by Professor Jan Torzewski, the trial achieved a zero percent rate for several critical safety metrics through the 48-month observation window.

Specifically, investigators recorded no instances of cardiac death, no target-vessel myocardial infarction, and no definite or probable scaffold thrombosis.

The aggregate target lesion failure rate settled at 3.5 percent.

This figure was driven entirely by cases of clinically driven target lesion revascularization, with only a single intervention occurring beyond the initial 12-month resorption period of the magnesium structure.

The Freesolve system belongs to an emerging class of bioresorbable implants designed to provide temporary mechanical support to narrowing coronary arteries, maintaining structural integrity during the acute vascular healing phase before dissolving completely within a one-year timeframe.

This transient footprint aims to reduce the long-term foreign-body risks, localized inflammation, and late-stage stent thrombosis frequently associated with permanent metal drug-eluting stents.

The long-term safety profile delivered by the BIOMAG-I cohort provides a foundational baseline for Teleflex’s broader interventional cardiology portfolio.

Corporate leadership indicated that these four-year clinical milestones will support the execution of the company's ongoing BIOMAG-II trial and its pending BIOMAG-III randomized controlled trials, which are designed to further position the bioresorbable magnesium platform against modern drug-eluting therapeutic standards in global healthcare markets.